STOCK TITAN
  1. Home
  2. Sec-filings
  3. POM
  4. [6-K] POMDOCTOR Ltd Current Report (Foreign Issuer)

POMDOCTOR (NASDAQ: POM) outlines AI-driven chronic disease management vision

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

POMDOCTOR LIMITED outlined its strategy to build an AI-enabled chronic disease management ecosystem, integrating artificial intelligence, remote patient monitoring, wearable technologies and real-world healthcare data. The company aims to shift care from reactive treatment toward predictive, continuous and personalized healthcare services.

The update highlights third-party research projecting rapid growth for AI chronic disease prevention and digital chronic disease management markets over the next decade, underscoring rising demand for predictive analytics and remote monitoring solutions. Management emphasized continued investment in technology capabilities and ecosystem partnerships to support its long-term vision for predictive healthcare infrastructure.

Positive

  • None.

Negative

  • None.
AI chronic disease prevention market 2026 US$30.2 billion Global AI chronic disease prevention market size in 2026, Dimension Market Research
AI chronic disease prevention market 2035 US$488.4 billion Projected global AI chronic disease prevention market size by 2035
AI chronic disease prevention CAGR 36.2% CAGR Projected 2026–2035 compound annual growth rate, Dimension Market Research
Chronic disease management tech 2025 US$7.21 billion Global chronic disease management technology market size in 2025, Data Bridge Market Research
Chronic disease management tech 2033 US$15.01 billion Projected market size by 2033, Data Bridge Market Research
Chronic disease management tech CAGR 9.6% CAGR Projected 2025–2033 compound annual growth rate, Data Bridge Market Research
Chronic disease management industry 2021 US$4.9 billion Global chronic disease management industry size in 2021, Allied Market Research
Chronic disease management industry 2031 US$14.88 billion Projected industry size by 2031, Allied Market Research
AI-enabled chronic disease management ecosystem financial
"highlighted its continued efforts in building an AI-powered chronic disease management ecosystem"
remote patient monitoring financial
"integrating artificial intelligence (“AI”), remote patient monitoring (“RPM”), wearable technologies"
Remote patient monitoring is the ongoing collection and transmission of a person’s health data (such as heart rate, blood sugar, or blood pressure) from home or another non-clinical setting to healthcare providers using connected devices and secure networks. For investors, it matters because it can reduce hospital visits, create steady service and device revenue, and change how care is paid for—think of it as a home security system for health that can lower costs and improve outcomes.
predictive healthcare financial
"growing demand for predictive healthcare"
real-world healthcare data financial
"wearable technologies and real-world healthcare data to evolve toward a predictive"
Real-world healthcare data are health and medical information collected outside controlled clinical trials—examples include doctor and hospital records, insurance billing, pharmacy fills, patient surveys and wearable device readings. Investors treat this data like a business dashboard showing how treatments and products perform in everyday life, helping estimate demand, detect safety or usage trends, assess regulatory risk, and make more informed bets on a company’s commercial prospects.
forward-looking statements regulatory
"Certain statements in this announcement are forward-looking statements."
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 6-K: How Foreign Companies Report to the SEC →

FAQ

What strategic focus did POMDOCTOR (POM) highlight in its latest 6-K?
POMDOCTOR emphasized its focus on building an AI-enabled chronic disease management ecosystem. The company is integrating artificial intelligence, remote patient monitoring, wearable technologies and real-world healthcare data to support predictive, continuous and personalized healthcare services aimed at improving long-term health management for chronic conditions.

How is POMDOCTOR (POM) using AI in chronic disease management?
POMDOCTOR is developing healthcare AI models that work with wearable devices, remote patient monitoring and physician resources. This integrated system aims to identify risks earlier, monitor patients continuously and support personalized interventions, moving care away from symptom-based treatment toward proactive, predictive healthcare management across the patient journey.

What market growth figures are cited in POMDOCTOR (POM)’s chronic disease strategy update?
The company cites Dimension Market Research projecting the global AI chronic disease prevention market rising from US$30.2 billion in 2026 to US$488.4 billion by 2035, and other firms forecasting strong growth in chronic disease management technologies, including digital health tools, predictive analytics and remote monitoring solutions worldwide.

What ecosystem components is POMDOCTOR (POM) integrating in its healthcare platform?
The company is integrating artificial intelligence, wearable technologies, remote patient monitoring capabilities, physician resources and healthcare payment networks. By connecting these elements with real-world healthcare data, POMDOCTOR aims to build infrastructure for predictive, continuous healthcare services designed to enhance outcomes for patients and providers.

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 6-K

 

 

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of July 2026

 

Commission file number: 001-42749

 

 

 

POMDOCTOR LIMITED

 

 

 

Yongxu Industrial Park
No.19-23 Hejing Road, Dongsha Street
Liwan District, Guangzhou 510000

People’s Republic of China

(Address of principal executive offices)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒    Form 40-F ☐

 

 

 

 

 

 

EXHIBIT INDEX

 

Exhibit No.   Description
99.1   Press Release—POMDOCTOR LIMITED Continues to Advance AI-Enabled Chronic Disease Management Strategy Amid Growing Demand for Predictive Healthcare

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  POMDOCTOR LIMITED
   
  /s/ Zhenyang Shi
  Zhenyang Shi
  Chairman and Chief Executive Officer

 

Date: July 9, 2026

 

 

2

 

 

Exhibit 99.1

 

POMDOCTOR LIMITED Continues to Advance AI-Enabled Chronic Disease Management Strategy Amid Growing Demand for Predictive Healthcare

 

GUANGZHOU, China, July 9, 2026 /PRNewswire/ -- POMDOCTOR LIMITED (the “Company”) (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today highlighted its continued efforts in building an AI-powered chronic disease management ecosystem. The Company is integrating artificial intelligence (“AI”), remote patient monitoring (“RPM”), wearable technologies and real-world healthcare data to evolve toward a predictive, continuous and personalized healthcare service provider.

 

The Company believes that the global healthcare industry is undergoing a significant transformation from traditional reactive treatment models toward proactive health prediction and long-term disease management, as increasing chronic disease prevalence, rapid advancements in AI technologies and broader adoption of remote monitoring solutions accelerate the shift.

 

Multiple market reports released recently have highlighted this industry trend, specifically noting the accelerating adoption of AI-driven healthcare and chronic disease management technologies. According to Dimension Market Research, the global AI chronic disease prevention market is projected to grow from approximately US$30.2 billion in 2026 to US$488.4 billion by 2035, representing a compound annual growth rate (“CAGR”) of 36.2%, driven by increasing demand for AI-driven predictive models and intelligent healthcare solutions across major chronic disease categories.

 

Data Bridge Market Research predicts that the global chronic disease management technology market will grow from US$7.21 billion in 2025 to US$15.01 billion by 2033, at a CAGR of 9.6%, driven by growing adoption of digital health technologies, predictive analytics and remote monitoring solutions. Similarly, Allied Market Research also estimates that the global chronic disease management industry will increase from US$4.9 billion in 2021 to US$14.88 billion by 2031, reflecting rising demand for technology-enabled chronic disease management solutions.

 

Building an AI-Enabled Predictive Healthcare Ecosystem

 

Aligned with these industry trends, POM continues to strengthen its strategic focus on AI-enabled chronic disease management by integrating healthcare AI models, wearable technologies, RPM capabilities, physician resources and healthcare payment networks into a connected healthcare ecosystem.

 

Unlike traditional healthcare models that primarily focus on treatment after symptoms occur, POM aims to support earlier risk identification, continuous monitoring and personalized intervention throughout the healthcare journey.

 

 

 

 

The Company continues to develop its healthcare intelligence framework based on several key components:

 

●AI Analytics and Predictive Capabilities: Leveraging AI technologies and real-world healthcare data to analyze potential health risks, evaluate patient trends and support more personalized health management.

 

●Remote Patient Monitoring and Wearable Integration: Utilizing connected devices and continuous health data collection to extend healthcare management beyond traditional clinical settings.

 

●Physician Network and Medical Services: Combining technology-driven insights with professional healthcare resources to provide more effective intervention and long-term chronic disease management.

 

●Healthcare Ecosystem Partnerships: Exploring collaboration opportunities across healthcare providers, payers and other ecosystem participants to support more integrated and value-based healthcare services.

 

Management Commentary

 

Mr. Zhenyang Shi, Chairman and Chief Executive Officer of POMDOCTOR, commented: “The healthcare industry is entering a new era where AI, continuous health data and connected technologies are accelerating the transformation of chronic disease management. With increasing demand for proactive healthcare solutions, we believe AI-powered predictive capabilities and remote monitoring technologies will play an increasingly important role in improving long-term health management.

 

“At POMDOCTOR, we are building an integrated healthcare ecosystem that connects artificial intelligence, wearable technologies, physician resources, healthcare payment networks and real-world healthcare data. By combining these capabilities, we aim to advance the transition from reactive treatment toward predictive, personalized and continuous healthcare management. Looking ahead, we will continue strengthening our technology capabilities, expanding ecosystem partnerships and advancing our vision of building the infrastructure for the future of predictive healthcare.”

 

About POMDOCTOR LIMITED

 

POMDOCTOR LIMITED (NASDAQ: POM) is a digital healthcare company focused on advancing AI-enabled healthcare solutions and expanding predictive healthcare capabilities. The Company leverages physician resources, wearable technologies, artificial intelligence, healthcare payment networks and real-world healthcare data to support more personalized, continuous and data-driven healthcare services. Building upon its established healthcare platform and physician network, POM is pursuing the development of a predictive healthcare data and services infrastructure designed to improve healthcare outcomes and create long-term value for patients, healthcare providers and other ecosystem participants. For more information, please visit the Company’s website: http://ir.7shiliu.com.

 

2

 

 

Forward-Looking Statements

 

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s filings with the SEC.

 

For more information, please contact:

 

POMDOCTOR LIMITED
Investor Relations Department
Email: ir@7lk.com

 

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com

 

 

3

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases